Considering prior treatment received, it accounted for the smallest proportion (9.4%) in the group of patients who received DMD before the investigational oral drug, and therefore, the drug was the least frequent choice as the first treatment of MS among the four patient groups. Here, DMD is linked to myeloid sarcoma.